RMP–REMS Interactive Assistant

RMP–REMS Interactive Assistant

RMP–REMS Interactive Assistant

Design & teach Risk Management Plans (EU) and REMS (US) across development & post‑marketing

Abbreviations & How to Fill Each Section

Common Abbreviations

  • RMP: Risk Management Plan (EU)
  • REMS: Risk Evaluation & Mitigation Strategy (US)
  • ETASU: Elements to Assure Safe Use (REMS component)
  • IIR: Important Identified Risk (confirmed association)
  • IPR: Important Potential Risk (suspected association)
  • MI: Missing Information (gaps, e.g., pregnancy, long‑term)
  • PV: Pharmacovigilance
  • PASS: Post‑Authorisation Safety Study
  • PAES: Post‑Authorisation Efficacy Study
  • PSUR/PBRER: Periodic Safety Update Report / Benefit‑Risk Evaluation Report
  • ICSR: Individual Case Safety Report
  • SmPC: Summary of Product Characteristics (EU label)
  • JCV: JC virus
  • PML: Progressive Multifocal Leukoencephalopathy
  • HCP: Healthcare Professional
  • ANC: Absolute Neutrophil Count
  • AF: Atrial Fibrillation  •  VTE: Venous Thromboembolism
  • ATMP: Advanced Therapy Medicinal Product
  • EMA: European Medicines Agency  •  FDA: US Food & Drug Administration
  • MA: Marketing Authorisation
  • PPP: Pregnancy Prevention Programme
  • RMM: Risk Minimisation Measure

Quick How‑To (Best‑Practice Tips)

  1. Setup & Context — Pick Jurisdiction (EU/US/Both), Lifecycle Phase, and Product Type. In Indication/Population, use who/when (e.g., “Women of child‑bearing potential with severe acne”). In Mechanism, add the biological reason (e.g., “retinoid teratogenicity”).
  2. Safety Specification — Add each safety concern as a card:
    • IIR for confirmed risks (e.g., “Agranulocytosis” in clozapine).
    • IPR for suspected risks (e.g., “Immune‑mediated hepatitis” for a new IO drug).
    • MI for gaps (e.g., “Limited data in pregnancy”).
    • Populate Population (who is at risk), Rationale (why it can occur), and Evidence (what supports it).
  3. PV Plan — Tick routine PV (signal detection, PSURs). Add Additional PV (PASS/registries) only when needed to characterise a risk or MI. Title = what it is; Objective = question to answer; Endpoints = how you’ll measure; Timeline = when.
  4. Risk Minimisation — In Routine, list label/SmPC items (warnings, dosing, CIs). Add Additional Measures for high‑impact risks (e.g., PPP, lab monitoring, prescriber certification). For each measure, define Metrics:
    • Process: % prescribers trained; % negative pregnancy tests before dispense.
    • Outcome: fetal exposure rate; agranulocytosis incidence; major‑bleed admissions.
  5. Jurisdiction — EU: watch Parts II/III/V status chips. US: tick applicable REMS components (Medication Guide, ETASU, Implementation System).
  6. Examples — Use the loader to prefill (Isotretinoin, Clozapine, Natalizumab, DOACs). Review and customise.
  7. Export — Generate the narrative summary, copy for your dossier, download JSON for reuse, or print to PDF. Always align with current EMA/FDA guidance.

REMS vs RMP – Quick Compare

REMS (US) — triggered for select high‑risk medicines when labeling alone is insufficient; may include Medication Guides, Communication Plans, ETASU (e.g., prescriber certification, restricted distribution, mandatory testing), and Implementation Systems.
  • Focus: Specific serious risks
  • Scope: Only some drugs
  • Examples: Isotretinoin (iPLEDGE), Clozapine, ER/LA Opioids, Thalidomide/Lenalidomide
RMP (EU) — required for virtually all new medicines; includes Safety Specification (IIR/IPR/Missing Info), PV Plan (routine + additional), Risk Minimization (routine + additional), and effectiveness evaluation.
  • Focus: Full life‑cycle management
  • Scope: All new drugs (and major changes)
  • Examples: Isotretinoin PPP, Natalizumab (PML monitoring), DOACs education + reversal, Clozapine monitoring

Setup & Context

Completion
0/0 required fields

Safety Specification (IIR / IPR / Missing Information)

Add important identified risks (IIR), important potential risks (IPR), or missing information.

Pharmacovigilance Plan

PASS, registries, active surveillance, DB studies.

Risk Minimization Measures

Education, PPP, lab monitoring, restricted distribution, registries, etc.
How will effectiveness be evaluated?

Jurisdiction‑Specific Sections

EU – RMP Parts

PartContentStatus
Part IRMP Summary (public)Pending
Part IISafety Specification (IIR/IPR/Missing Info)Pending
Part IIIPharmacovigilance PlanPending
Part IVPAES (if applicable)N/A
Part VRisk Minimization MeasuresPending
Part VISummary of RMPPending

US – REMS Components

Load Case Examples

Why it matters (context)

Quick Quiz

Export / Print

Educational tool. For training and draft planning only. Always align final RMP/REMS with current EMA/FDA guidance & product‑specific conditions.